Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04250064

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma (LoBULarDIPG)

Sponsor: Tata Memorial Centre

Conditions DIPG

Interventions Bevacizumab Injection Ultra-low-dose RT

Updated 9 times since 2020 Last updated: Apr 8, 2025 Started: Feb 4, 2020 Primary completion: Dec 31, 2027 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates DIPG and is currently actively recruiting participants. Tata Memorial Centre leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

May 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — May 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Jun 2022 — Dec 2023 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

May 2021 — Jun 2022 [monthly]

Recruiting PHASE2
Jan 2021 — May 2021 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2020 — Apr 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tata Memorial Centre

Data source: Tata Memorial Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mumbai, India